Ignite Creation Date:
2024-05-05 @ 4:51 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00328198
Status:
COMPLETED
Last Update Posted:
2014-03-13
First Post:
2006-05-18
Brief Title:
Subcutaneous Alemtuzumab CAMPATH MabCampath in RelapsedRefractory B-Cell Chronic Lymphocytic Leukemia
Sponsor:
Genzyme a Sanofi Company
Organization:
Sanofi
Study Overview
Official Title:
A Phase II Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Alemtuzumab CAMPATH MabCampath in Patients With Previously Treated B-Cell Chronic Lymphocytic Leukemia
Status:
COMPLETED
Status Verified Date:
2014-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase II open-label prospective multicenter study to evaluate the efficacy and safety of subcutaneously administered alemtuzumab CAMPATH MabCampath as therapy for patients with relapsed or refractory B-CLL who have been previously treated
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2005-005074-69 | EUDRACT_NUMBER | None | None |